Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment

1.

Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V, CTD-ILD EATFoUFo (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46(4):976–987. https://doi.org/10.1183/13993003.00150-2015CrossRefPubMed

2.

Wells AU, Denton CP (2014) Interstitial lung disease in connective tissue disease–mechanisms and management. Nat Rev Rheumatol 10(12):728–739. https://doi.org/10.1038/nrrheum.2014.149CrossRefPubMed

3.

Levi Y, Israeli-Shani L, Kuchuk M, Epstein Shochet G, Koslow M, Shitrit D (2018) Rheumatological assessment is important for interstitial lung disease diagnosis. J Rheumatol 45(11):1509–1514. https://doi.org/10.3899/jrheum.171314CrossRefPubMed

4.

Cottin V, Brown KK (2019) Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 20(1):13. https://doi.org/10.1186/s12931-019-0980-7CrossRefPubMedPubMedCentral

5.

Akter T, Silver RM, Bogatkevich GS (2014) Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Curr Rheumatol Rep 16(4):411. https://doi.org/10.1007/s11926-014-0411-1CrossRefPubMed

6.

McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, Tan FK, Zhou X, Ahn C, Feghali-Bostwick CA, Fritzler M, Arnett FC, Mayes MD (2007) Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 57(2):318–326. https://doi.org/10.1002/art.22532CrossRefPubMed

7.

Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283–1289CrossRef

8.

Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr (1985) Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 28(7):759–767CrossRef

9.

Schurawitzki H, Stiglbauer R, Graninger W, Herold C, Polzleitner D, Burghuber OC, Tscholakoff D (1990) Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 176(3):755–759. https://doi.org/10.1148/radiology.176.3.2389033CrossRefPubMed

10.

Steele R, Hudson M, Lo E, Baron M, Canadian Scleroderma Research G (2012) Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 64(4):519–524. https://doi.org/10.1002/acr.21583CrossRef

11.

Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, Speich R, Frauenfelder T, Distler O (2015) Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 67(12):3256–3261. https://doi.org/10.1002/art.39405CrossRefPubMed

12.

Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165(12):1581–1586. https://doi.org/10.1164/rccm.2106012CrossRefPubMed

13.

Kim DS, Yoo B, Lee JS, Kim EK, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Colby TV, Kitiaichi M (2002) The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 19(2):121–127PubMed

14.

Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP, Scleroderma Lung Study Research G (2008) High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 134(2):358–367. https://doi.org/10.1378/chest.07-2444CrossRefPubMed

15.

Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66(6):754–763. https://doi.org/10.1136/ard.2006.062901CrossRefPubMedPubMedCentral

16.

Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr, Feghali-Bostwick CA (2009) Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 61(7):958–965. https://doi.org/10.1002/art.24586CrossRefPubMedPubMedCentral

17.

Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119(10):1005–1013CrossRef

18.

Sacks DG, Okano Y, Steen VD, Curtiss E, Shapiro LS, Medsger TA Jr (1996) Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 23(4):639–642PubMed

19.

Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, Fritzler MJ, Canadian Scleroderma Research G (2012) Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14(2):R50. https://doi.org/10.1186/ar3763CrossRefPubMedPubMedCentral

20.

Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, Silver RM, Scleroderma Lung Study Research G (2009) Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 36(4):773–780. https://doi.org/10.3899/jrheum.080633CrossRefPubMed

21.

Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P (2005) HLA markers for susceptibility and expression in scleroderma. J Rheumatol 32(8):1481–1487PubMed

22.

Peljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, Carns M, Schwarz M, Varga J, Schwartz DA (2012) The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 142(6):1584–1588. https://doi.org/10.1378/chest.12-0110CrossRefPubMedPubMedCentral

23.

Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, Collard HR, Ryerson CJ (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146(2):422–436. https://doi.org/10.1378/chest.13-2626CrossRefPubMed

24.

Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254. https://doi.org/10.1164/rccm.200706-877OCCrossRefPubMed

25.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU (2017) Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 69(8):1670–1678. https://doi.org/10.1002/art.40130CrossRefPubMed

26.

Ciancio N, Pavone M, Torrisi SE, Vancheri A, Sambataro D, Palmucci S, Vancheri C, Di Marco F, Sambataro G (2019) Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidiscip Respir Med 14:17. https://doi.org/10.1186/s40248-019-0179-2CrossRefPubMedPubMedCentral

27.

Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE Jr, Collard HR, Lee JS (2017) Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model. Chest 152(5):999–1007. https://doi.org/10.1016/j.chest.2017.06.009CrossRefPubMedPubMedCentral

28.

Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, Ye S, Siegert E, Allanore Y, Hoffmann-Vold AM, Distler O (2018) Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis 77(9):1326–1332. https://doi.org/10.1136/annrheumdis-2018-213201CrossRefPubMed

29.

Ryerson CJ, O'Connor D, Dunne JV, Schooley F, Hague CJ, Murphy D, Leipsic J, Wilcox PG (2015) Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis. Chest 148(5):1268–1275. https://doi.org/10.1378/chest.15-0003CrossRefPubMed

30.

Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP, Scleroderma Lung Study Research G (2008) Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 177(1):91–98. https://doi.org/10.1164/rccm.200705-655OCCrossRefPubMed

31.

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research G (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666. https://doi.org/10.1056/NEJMoa055120CrossRefPubMed

32.

Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, Black CM, du Bois RM, Wells AU (2007) Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 56(6):2005–2012. https://doi.org/10.1002/art.22696CrossRefPubMed

33.

Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M, Delannoy V, Queyrel V, Duhamel A, Matran R, De Groote P, Hatron PY (2006) High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 33(9):1789–1801PubMed

34.

Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, Negrini S, Indiveri F, Tutuian R, Savarino V, Ghio M (2009) Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 179(5):408–413. https://doi.org/10.1164/rccm.200808-1359OCCrossRefPubMed

35.

Richardson C, Agrawal R, Lee J, Almagor O, Nelson R, Varga J, Cuttica MJ, Dematte JD, Chang RW, Hinchcliff ME (2016) Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin Arthritis Rheum 46(1):109–114. https://doi.org/10.1016/j.semarthrit.2016.02.004CrossRefPubMedPubMedCentral

36.

Morales-Cardenas A, Perez-Madrid C, Arias L, Ojeda P, Mahecha MP, Rojas-Villarraga A, Carrillo-Bayona JA, Anaya JM (2016) Pulmonary involvement in systemic sclerosis. Autoimmun Rev 15(11):1094–1108. https://doi.org/10.1016/j.autrev.2016.07.025CrossRefPubMed

37.

Bauer PR, Schiavo DN, Osborn TG, Levin DL, St Sauver J, Hanson AC, Schroeder DR, Ryu JH (2013) Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest 144(2):571–577. https://doi.org/10.1378/chest.12-2768CrossRefPubMedPubMedCentral

38.

Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, Wells AU, Denton CP (2014) Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 66(6):1625–1635. https://doi.org/10.1002/art.38390CrossRefPubMed

39.

Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, Roth MD, Goldin J, Elashoff R, Seibold JR, Saggar R, Tashkin DP (2011) Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 63(10):3078–3085. https://doi.org/10.1002/art.30467CrossRefPubMedPubMedCentral

40.

Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11):2437–2444. https://doi.org/10.1002/1529-0131(200011)43:11<2437:AID-ANR10>3.0.CO;2-UCrossRefPubMed

41.

Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66(7):940–944. https://doi.org/10.1136/ard.2006.066068CrossRefPubMedPubMedCentral

42.

Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Muller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumanovics G, Coleiro B, Feierl E, Szucs G, Von Muhlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kotter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815. https://doi.org/10.1136/ard.2009.114264CrossRefPubMed

43.

Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G, Scleroderma Lung Study Research G (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176(10):1026–1034. https://doi.org/10.1164/rccm.200702-326OCCrossRefPubMedPubMedCentral

44.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study III (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719. https://doi.org/10.1016/S2213-2600(16)30152-7CrossRefPubMedPubMedCentral

45.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, Investigators ST (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380(26):2518–2528. https://doi.org/10.1056/NEJMoa1903076CrossRefPubMed

46.

Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E (2016) An open-label, Phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol 43(9):1672–1679. https://doi.org/10.3899/jrheum.151322CrossRefPubMed

47.

Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Muller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387(10038):2630–2640. https://doi.org/10.1016/S0140-6736(16)00232-4CrossRefPubMed

48.

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Muller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77(2):212–220. https://doi.org/10.1136/annrheumdis-2017-211682CrossRefPubMed

49.

van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kotter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quere I, Rich E, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socie G, Gratwohl A, Tyndall A, Group EESS (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498. https://doi.org/10.1001/jama.2014.6368CrossRefPubMed

50.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE, Investigators SS (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378(1):35–47CrossRef

51.

Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49(2):271–280. https://doi.org/10.1093/rheumatology/kep093CrossRef

52.

Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O, group ERs (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74(6):1188–1194. https://doi.org/10.1136/annrheumdis-2013-204522CrossRefPubMed

53.

Steen VD, Medsger TA Jr (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41(9):1613–1619. https://doi.org/10.1002/1529-0131(199809)41:9<1613:AID-ART11>3.0.CO;2-OCrossRefPubMed

54.

Ando K, Motojima S, Doi T, Nagaoka T, Kaneko N, Aoshima M, Takahashi K (2013) Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respir Investig 51(2):69–75. https://doi.org/10.1016/j.resinv.2012.12.002CrossRefPubMed

55.

Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25(2):205–212. https://doi.org/10.1007/s10067-005-1157-yCrossRefPubMed

56.

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970. https://doi.org/10.1002/art.22204CrossRefPubMed

57.

Miele CH, Schwab K, Saggar R, Duffy E, Elashoff D, Tseng CH, Weigt S, Charan D, Abtin F, Johannes J, Derhovanessian A, Conklin J, Ghassemi K, Khanna D, Siddiqui O, Ardehali A, Hunter C, Kwon M, Biniwale R, Lo M, Volkmann E, Torres Barba D, Belperio JA, Sayah D, Mahrer T, Furst DE, Kafaja S, Clements P, Shino M, Gregson A, Kubak B, Lynch JP, 3rd, Ross D, Saggar R (2016) Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann Am Thorac Soc 13(6):793–802.

58.

Pradere P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, Reynaud-Gaubert M, Claustre J, Borgne AL, Holm AM, Schultz HH, Knoop C, Godinas L, Fisher AJ, Hirschi S, Gottlieb J, Le Pavec J, Working Group on Heart/Lung Transplantation in Systemic S (2018) Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. J Heart Lung Transpl 37(7):903–911. https://doi.org/10.1016/j.healun.2018.03.003CrossRef

59.

Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF (2019) Thoracic manifestations of rheumatoid arthritis. Clin Chest Med 40(3):545–560. https://doi.org/10.1016/j.ccm.2019.05.003CrossRefPubMedPubMedCentral

60.

Tanoue LT (1998) Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 19(4):667–685CrossRef

61.

Lee HK, Kim DS, Yoo B, Seo JB, Rho JY, Colby TV, Kitaichi M (2005) Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127(6):2019–2027. https://doi.org/10.1378/chest.127.6.2019CrossRefPubMed

62.

Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, Swigris JJ (2019) Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol 46(4):360–369. https://doi.org/10.3899/jrheum.171315CrossRefPubMed

63.

Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, Lake FR (1997) Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156(2 Pt 1):528–535. https://doi.org/10.1164/ajrccm.156.2.9609016CrossRefPubMed

64.

Habib HM, Eisa AA, Arafat WR, Marie MA (2011) Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol 30(2):217–221. https://doi.org/10.1007/s10067-010-1492-5CrossRefPubMed

65.

Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, Fukuda J (1994) Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 21(1):33–36PubMed

66.

Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, Emoto T, Matsumoto T, Lynch DA (2004) Rheumatoid arthritis-related lung diseases: CT findings. Radiology 232(1):81–91. https://doi.org/10.1148/radiol.2321030174CrossRefPubMed

67.

Kim EJ, Collard HR, King TE Jr (2009) Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 136(5):1397–1405. https://doi.org/10.1378/chest.09-0444CrossRefPubMedPubMedCentral

68.

Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A, British Rheumatoid Interstitial Lung N (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology (Oxford) 53(9):1676–1682. https://doi.org/10.1093/rheumatology/keu165CrossRef

69.

Mori S, Koga Y, Sugimoto M (2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 106(11):1591–1599. https://doi.org/10.1016/j.rmed.2012.07.006CrossRefPubMed

70.

Shaw M, Collins BF, Ho LA, Raghu G (2015) Rheumatoid arthritis-associated lung disease. Eur Respir Rev 24(135):1–16. https://doi.org/10.1183/09059180.00008014CrossRefPubMed

71.

Zhu J, Zhou Y, Chen X, Li J (2014) A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 41(7):1282–1289. https://doi.org/10.3899/jrheum.131341CrossRefPubMed

72.

Harlow L, Rosas IO, Gochuico BR, Mikuls TR, Dellaripa PF, Oddis CV, Ascherman DP (2013) Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 65(4):869–879. https://doi.org/10.1002/art.37881CrossRefPubMed

73.

Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y, Ge SX, Huang H, Lin Q, Liu W, Cai Y, Koontz D, Fuhrman CR, Golzarri MF, Liu Y, Hatabu H, Nishino M, Araki T, Dellaripa PF, Oddis CV, Rosas IO, Ascherman DP (2015) Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 67(1):28–38. https://doi.org/10.1002/art.38904CrossRefPubMedPubMedCentral

74.

Maniwa K, Ogushi F, Tani K, Ohmoto Y, Muraguchi M, Sone S (2000) Increased incidence of autoantibodies to interleukin-1a in rheumatoid arthritis with interstitial lung disease. Respirology 5(4):315–320PubMed

75.

Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, Kamatani N, Kashiwazaki S (2000) KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 27(5):1164–1170PubMed

76.

Garcia JG, Parhami N, Killam D, Garcia PL, Keogh BA (1986) Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis. Am Rev Respir Dis 133(3):450–454. https://doi.org/10.1164/arrd.1986.133.3.450CrossRefPubMed

77.

Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, Gonzalez-Perez MI, Mejia M, Buendia-Roldan I, Falfan-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Liote H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clement A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieude P (2018) MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 379(23):2209–2219. https://doi.org/10.1056/NEJMoa1801562CrossRefPubMedPubMedCentral

78.

Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, Lee JS, King TE Jr, Collard HR (2010) Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 35(6):1322–1328. https://doi.org/10.1183/09031936.00092309CrossRefPubMed

79.

Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL (2017) Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 69(3):542–549. https://doi.org/10.1002/art.39971CrossRefPubMedPubMedCentral

80.

Song JW, Lee HK, Lee CK, Chae EJ, Jang SJ, Colby TV, Kim DS (2013) Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 30(2):103–112PubMed

81.

Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56(8):622–627CrossRef

82.

Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ (2016) Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 47(2):588–596. https://doi.org/10.1183/13993003.00357-2015CrossRefPubMed

83.

Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Suda T, Chida K (2013) Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 3(9):e003132. https://doi.org/10.1136/bmjopen-2013-003132CrossRefPubMedPubMedCentral

84.

Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66(4):803–812. https://doi.org/10.1002/art.38322CrossRefPubMed

85.

Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Lokke A, Bendstrup E, Ellingsen T (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76(10):1700–1706. https://doi.org/10.1136/annrheumdis-2017-211138CrossRefPubMed

86.

Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D, Kawabata Y, Sugita Y (2011) Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37(6):1411–1417. https://doi.org/10.1183/09031936.00019210CrossRefPubMed

87.

Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, Huie TJ, Krishnamoorthy M, Meehan RT, Olson AL, Solomon JJ, Swigris JJ (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640–646. https://doi.org/10.3899/jrheum.121043CrossRefPubMedPubMedCentral

88.

Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, Dass S, Emery P (2017) Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford) 56(8):1348–1357. https://doi.org/10.1093/rheumatology/kex072CrossRef

89.

Fui A, Bergantini L, Selvi E, Mazzei MA, Bennett D, Pieroni MG, Rottoli P, Bargagli E (2019) Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J. https://doi.org/10.1111/imj.14306CrossRef

90.

Fernandez-Diaz C, Loricera J, Castaneda S, Lopez-Mejias R, Ojeda-Garcia C, Olive A, Rodriguez-Muguruza S, Carreira PE, Perez-Sandoval T, Retuerto M, Cervantes-Perez EC, Flores-Robles BJ, Hernandez-Cruz B, Urruticoechea A, Maiz-Alonso O, Arboleya L, Bonilla G, Hernandez-Rodriguez I, Palma D, Delgado C, Exposito-Molinero R, Ruibal-Escribano A, Alvarez-Rodriguez B, Blanco-Madrigal J, Bernal JA, Vela-Casasempere P, Rodriguez-Gomez M, Fito C, Ortiz-Sanjuan F, Narvaez J, Moreno M, Lopez-Corbeto M, Mena-Vazquez N, Aguilera-Cros C, Romero-Yuste S, Ordonez S, Villa-Blanco I, Gonzelez-Vela MC, Mora-Cuesta V, Palmou-Fontana N, Hernandez JL, Gonzalez-Gay MA, Blanco R (2018) Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum 48(1):22–27. https://doi.org/10.1016/j.semarthrit.2017.12.012CrossRefPubMed

91.

Manfredi A, Cassone G, Furini F, Gremese E, Venerito V, Atzeni F, Arrigoni E, Della Casa G, Cerri S, Govoni M, Petricca L, Iannone F, Salvarani C, Sebastiani M (2019) Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study. Intern Med J. https://doi.org/10.1111/imj.14670CrossRef

92.

Kiely P, Busby AD, Nikiphorou E, Sullivan K, Walsh DA, Creamer P, Dixey J, Young A (2019) Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 9(5):e028466. https://doi.org/10.1136/bmjopen-2018-028466CrossRefPubMedPubMedCentral

93.

Mochizuki T, Ikari K, Yano K, Sato M, Okazaki K (2019) Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. Mod Rheumatol 29(3):413–417. https://doi.org/10.1080/14397595.2018.1481566CrossRefPubMed

94.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK, Investigators IT (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381(18):1718–1727. https://doi.org/10.1056/NEJMoa1908681CrossRefPubMed

95.

Courtwright AM, El-Chemaly S, Dellaripa PF, Goldberg HJ (2017) Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease. J Heart Lung Transplant 36(7):763–769. https://doi.org/10.1016/j.healun.2016.12.013CrossRefPubMed

96.

Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S (2014) Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 33(5):514–520. https://doi.org/10.1016/j.healun.2014.01.858CrossRefPubMed

97.

Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63(11):3439–3447. https://doi.org/10.1002/art.30513CrossRefPubMed

98.

Morisset J, Johnson C, Rich E, Collard HR, Lee JS (2016) Management of myositis-related interstitial lung disease. Chest 150(5):1118–1128. https://doi.org/10.1016/j.chest.2016.04.007CrossRefPubMed

99.

Ikeda S, Arita M, Misaki K, Mishima S, Takaiwa T, Nishiyama A, Ito A, Furuta K, Yokoyama T, Tokioka F, Noyama M, Yoshioka H, Ishida T (2015) Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Springerplus 4:240. https://doi.org/10.1186/s40064-015-1013-8CrossRefPubMedPubMedCentral

100.

Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP (2009) Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 60(7):2183–2192. https://doi.org/10.1002/art.24631CrossRefPubMedPubMedCentral

101.

Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, Ryu JH (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182–1185. https://doi.org/10.1164/ajrccm.164.7.2103110CrossRefPubMed

102.

Solomon J, Swigris JJ, Brown KK (2011) Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 37(1):100–109. https://doi.org/10.1590/s1806-37132011000100015CrossRefPubMedPubMedCentral

103.

Zhang L, Wu G, Gao D, Liu G, Pan L, Ni L, Li Z, Wang Q (2016) Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS ONE 11(5):e0155381. https://doi.org/10.1371/journal.pone.0155381CrossRefPubMedPubMedCentral

104.

Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, Roblot P, Jouneau S, Hatron PY, Tiev KP, Vittecoq O, Noel D, Mouthon L, Menard JF, Jouen F (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11(10):739–745. https://doi.org/10.1016/j.autrev.2012.01.006CrossRefPubMed

105.

Cavagna L, Trallero-Araguas E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Zanframundo G, Morandi V, Meyer A, Pereira da Silva JA, Matos Costa CJ, Molberg O, Andersson H, Codullo V, Mosca M, Barsotti S, Neri R, Scire C, Govoni M, Furini F, Lopez-Longo FJ, Martinez-Barrio J, Schneider U, Lorenz HM, Doria A, Ghirardello A, Ortego-Centeno N, Confalonieri M, Tomietto P, Pipitone N, Rodriguez Cambron AB, Blazquez Canamero MA, Voll RE, Wendel S, Scarpato S, Maurier F, Limonta M, Colombelli P, Giannini M, Geny B, Arrigoni E, Bravi E, Migliorini P, Mathieu A, Piga M, Drott U, Delbrueck C, Bauhammer J, Cagnotto G, Vancheri C, Sambataro G, De Langhe E, Sainaghi PP, Monti C, Gigli Berzolari F, Romano M, Bonella F, Specker C, Schwarting A, Villa Blanco I, Selmi C, Ceribelli A, Nuno L, Mera-Varela A, Perez Gomez N, Fusaro E, Parisi S, Sinigaglia L, Del Papa N, Benucci M, Cimmino MA, Riccieri V, Conti F, Sebastiani GD, Iuliano A, Emmi G, Cammelli D, Sebastiani M, Manfredi A, Bachiller-Corral J, Sifuentes Giraldo WA, Paolazzi G, Saketkoo LA, Giorgi R, Salaffi F, Cifrian J, Caporali R, Locatelli F, Marchioni E, Pesci A, Dei G, Pozzi MR, Claudia L, Distler J, Knitza J, Schett G, Iannone F, Fornaro M, Franceschini F, Quartuccio L, Gerli R, Bartoloni E, Bellando Randone S, Zampogna G, Gonzalez Perez MI, Mejia M, Vicente E, Triantafyllias K, Lopez-Mejias R, Matucci-Cerinic M, Selva-O'Callaghan A, Castaneda S, Montecucco C, Gonzalez-Gay MA (2019) Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. https://doi.org/10.3390/jcm8112013CrossRefPubMedPubMedCentral

106.

Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, Christopher-Stine L (2013) Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 65(8):1307–1315. https://doi.org/10.1002/acr.21992CrossRef

107.

Takada T, Aoki A, Asakawa K, Sakagami T, Moriyama H, Narita I, Sato S (2015) Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis. Respir Med 109(9):1174–1180. https://doi.org/10.1016/j.rmed.2015.07.004CrossRefPubMed

108.

Fujisawa T, Hozumi H, Kono M, Enomoto N, Nakamura Y, Inui N, Nakashima R, Imura Y, Mimori T, Suda T (2017) Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases. Respir Investig 55(2):130–137. https://doi.org/10.1016/j.resinv.2016.09.006CrossRefPubMed

109.

Sclafani A, D'Silva KM, Little BP, Miloslavsky EM, Locascio JJ, Sharma A, Montesi SB (2019) Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody. Respir Res 20(1):256. https://doi.org/10.1186/s12931-019-1231-7CrossRefPubMedPubMedCentral

110.

Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T (2014) Prognostic factors for myositis-associated interstitial lung disease. PLoS ONE 9(6):e98824. https://doi.org/10.1371/journal.pone.0098824CrossRefPubMedPubMedCentral

111.

Johnson C, Rosen P, Lloyd T, Horton M, Christopher-Stine L, Oddis CV, Mammen AL, Danoff SK (2017) Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. Respir Med 130:52–54. https://doi.org/10.1016/j.rmed.2017.07.010CrossRefPubMed

112.

Lopez-Mejias R, Remuzgo-Martinez S, Genre F, Pulito-Cueto V, Rozas SMF, Llorca J, Fernandez DI, Cuesta VMM, Ortego-Centeno N, Gomez NP, Mera-Varela A, Martinez-Barrio J, Lopez-Longo FJ, Mijares V, Lera-Gomez L, Usetti MP, Laporta R, Perez V, Gafas AP, Gonzalez MAA, Calvo-Alen J, Romero-Bueno F, Sanchez-Pernaute O, Nuno L, Bonilla G, Balsa A, Hernandez-Gonzalez F, Grafia I, Prieto-Gonzalez S, Narvaez J, Trallero-Araguas E, Selva-O'Callaghan A, Gualillo O, Castaneda S, Cavagna L, Cifrian JM, Gonzalez-Gay MA (2020) Influence of MUC5B gene on antisynthetase syndrome. Sci Rep 10(1):1415. https://doi.org/10.1038/s41598-020-58400-0CrossRefPubMedPubMedCentral

113.

Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, Devulder B, Herson S, Levesque H, Courtois H (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622. https://doi.org/10.1002/art.10794CrossRefPubMed

114.

Takada K, Kishi J, Miyasaka N (2007) Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study. Mod Rheumatol 17(2):123–130. https://doi.org/10.1007/s10165-007-0553-3CrossRefPubMed

115.

Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G (2015) Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol 34(1):99–105. https://doi.org/10.1007/s10067-014-2803-zCrossRefPubMed

116.

Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ, Sanyal A, Mammen AL, Christopher-Stine L, Danoff SK (2019) Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest 156(5):896–906. https://doi.org/10.1016/j.chest.2019.05.023CrossRefPubMed

117.

Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-Hansen R, Garen T, Molberg O (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 54(8):1420–1428. https://doi.org/10.1093/rheumatology/kev004CrossRef

118.

Ge Y, Zhou H, Shi J, Ye B, Peng Q, Lu X, Wang G (2015) The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clin Rheumatol 34(12):2097–2103. https://doi.org/10.1007/s10067-015-3065-0CrossRefPubMed

119.

Cavagna L, Caporali R, Abdi-Ali L, Dore R, Meloni F, Montecucco C (2013) Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol 40(4):484–492. https://doi.org/10.3899/jrheum.121026CrossRefPubMed

120.

Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187(3):201–206. https://doi.org/10.1007/s00408-009-9146-6CrossRefPubMed

121.

Chen Z, Wang X, Ye S (2019) Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med 381(3):291–293. https://doi.org/10.1056/NEJMc1900045CrossRefPubMed

122.

Ameye H, Ruttens D, Benveniste O, Verleden GM, Wuyts WA (2014) Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. Transplant Proc 46(9):3147–3153. https://doi.org/10.1016/j.transproceed.2014.09.163CrossRefPubMed

123.

Watanabe M, Naniwa T, Hara M, Arakawa T, Maeda T (2010) Pulmonary manifestations in Sjogren's syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients. J Rheumatol 37(2):365–373. https://doi.org/10.3899/jrheum.090507CrossRefPubMed

124.

Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL (2013) Primary Sjogren's syndrome 1976–2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 3(11):e003569. https://doi.org/10.1136/bmjopen-2013-003569CrossRefPubMedPubMedCentral

125.

Sambataro G, Ferro F, Orlandi M, Sambataro D, Torrisi SE, Quartuccio L, Vancheri C, Baldini C, Matucci Cerinic M (2020) Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjgren's syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev 19(2):102447. https://doi.org/10.1016/j.autrev.2019.102447CrossRefPubMed

126.

Kurumagawa T, Kobayashi H, Motoyoshi K (2005) Potential involvement of subclinical Sjogren's syndrome in various lung diseases. Respirology 10(1):86–91. https://doi.org/10.1111/j.1440-1843.2005.00627.xCrossRefPubMed

127.

Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM (1985) Respiratory manifestations in primary Sjogren's syndrome. A clinical, functional, and histologic study. Chest 88(2):226–229CrossRef

128.

Papathanasiou MP, Constantopoulos SH, Tsampoulas C, Drosos AA, Moutsopoulos HM (1986) Reappraisal of respiratory abnormalities in primary and secondary Sjogren's syndrome. A controlled study. Chest 90(3):370–374CrossRef

129.

Vitali C, Tavoni A, Viegi G, Begliomini E, Agnesi A, Bombardieri S (1985) Lung involvement in Sjogren's syndrome: a comparison between patients with primary and with secondary syndrome. Ann Rheum Dis 44(7):455–461CrossRef

130.

Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality–a retrospective study based on registry data. Rheumatology (Oxford) 52(1):173–179. https://doi.org/10.1093/rheumatology/kes311CrossRef

131.

Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, Theander E, Bombardieri S, De Vita S, Mandl T, Ng WF, Kruize A, Tzioufas A, Vitali C, Force ESST (2015) Characterization of systemic disease in primary Sjogren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 54(12):2230–2238. https://doi.org/10.1093/rheumatology/kev200CrossRef

132.

Buvry C, Cassagnes L, Tekath M, Artigues M, Pereira B, Rieu V, Le Guenno G, Tournadre A, Ruivard M, Grobost V (2020) Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjogren syndrome. Respir Med 163:105895. https://doi.org/10.1016/j.rmed.2020.105895CrossRefPubMed

133.

Davidson BK, Kelly CA, Griffiths ID (2000) Ten year follow up of pulmonary function in patients with primary Sjogren's syndrome. Ann Rheum Dis 59(9):709–712CrossRef

134.

Hatron PY, Wallaert B, Gosset D, Tonnel AB, Gosselin B, Voisin C, Devulder B (1987) Subclinical lung inflammation in primary Sjogren's syndrome: relationship between bronchoalveolar lavage cellular analysis findings and characteristics of the disease. Arthritis Rheum 30(11):1226–1231CrossRef

135.

Dalavanga YA, Constantopoulos SH, Galanopoulou V, Zerva L, Moutsopoulos HM (1991) Alveolitis correlates with clinical pulmonary involvement in primary Sjogren's syndrome. Chest 99(6):1394–1397CrossRef

136.

Dalavanga YA, Voulgari PV, Georgiadis AN, Leontaridi C, Katsenos S, Vassiliou M, Drosos AA, Constantopoulos SH (2006) Lymphocytic alveolitis: a surprising index of poor prognosis in patients with primary Sjogren's syndrome. Rheumatol Int 26(9):799–804. https://doi.org/10.1007/s00296-005-0092-1CrossRefPubMed

137.

Salaffi F, Manganelli P, Carotti M, Baldelli S, Blasetti P, Subiaco S, Binci MC, Bichi Secchi E, Amici F, Cervini C (1998) A longitudinal study of pulmonary involvement in primary Sjogren's syndrome: relationship between alveolitis and subsequent lung changes on high-resolution computed tomography. Br J Rheumatol 37(3):263–269CrossRef

138.

Enomoto Y, Takemura T, Hagiwara E, Iwasawa T, Fukuda Y, Yanagawa N, Sakai F, Baba T, Nagaoka S, Ogura T (2013) Prognostic factors in interstitial lung disease associated with primary Sjogren's syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS ONE 8(9):e73774. https://doi.org/10.1371/journal.pone.0073774CrossRefPubMedPubMedCentral

139.

Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X, Club Rhumatismes et I, The French Society of R (2013) Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 72(6):1026–1031. https://doi.org/10.1136/annrheumdis-2012-202293CrossRefPubMed

140.

Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH (2006) Interstitial lung disease in primary Sjogren syndrome. Chest 130(5):1489–1495. https://doi.org/10.1378/chest.130.5.1489CrossRefPubMed

141.

Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR (1996) Interstitial lung disease in primary Sjogren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 154(3 Pt 1):794–799. https://doi.org/10.1164/ajrccm.154.3.8810621CrossRefPubMed

142.

Bertoli AM, Vila LM, Apte M, Fessler BJ, Bastian HM, Reveille JD, Alarcon GS, Group LS (2007) Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 16(6):410–417. https://doi.org/10.1177/0961203307079042CrossRef

143.

Nakano M, Hasegawa H, Takada T, Ito S, Muramatsu Y, Satoh M, Suzuki E, Gejyo F (2002) Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology 7(1):45–49CrossRef

144.

Mittoo S, Fell CD (2014) Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 35(2):249–254. https://doi.org/10.1055/s-0034-1371537CrossRefPubMed

145.

Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, Tarp U, Poulsen LH, van Overeem HG, Skaarup B, Hansen TM, Podenphant J, Halberg P (1998) A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol 17(6):468–477CrossRef

146.

Lee SS, Singh S, Link K, Petri M (2008) High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 38(1):41–54. https://doi.org/10.1016/j.semarthrit.2007.09.005CrossRefPubMedPubMedCentral

147.

Matthay RA, Schwarz MI, Petty TL, Stanford RE, Gupta RC, Sahn SA, Steigerwald JC (1975) Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 54(5):397–409. https://doi.org/10.1097/00005792-197509000-00003CrossRef

148.

Stoll T, Seifert B, Isenberg DA (1996) SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 35(3):248–254CrossRef

149.

Weinrib L, Sharma OP, Quismorio FP Jr (1990) A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 20(1):48–56CrossRef

150.

Greidinger EL, Hoffman RW (2005) Autoantibodies in the pathogenesis of mixed connective tissue disease. Rheum Dis Clin North Am 31(3):437–450. https://doi.org/10.1016/j.rdc.2005.04.004CrossRefPubMed

151.

Gunnarsson R, Aalokken TM, Molberg O, Lund MB, Mynarek GK, Lexberg AS, Time K, Dhainaut AS, Bertelsen LT, Palm O, Irgens K, Becker-Merok A, Nordeide JL, Johnsen V, Pedersen S, Proven A, Garabet LS, Gran JT (2012) Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 71(12):1966–1972. https://doi.org/10.1136/annrheumdis-2011-201253CrossRefPubMed

152.

Bodolay E, Szekanecz Z, Devenyi K, Galuska L, Csipo I, Vegh J, Garai I, Szegedi G (2005) Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 44(5):656–661. https://doi.org/10.1093/rheumatology/keh575CrossRef

153.

Vegh J, Szilasi M, Soos G, Devenyi K, Dezso B, Soltesz P, Zeher M, Szegedi G, Bodolay E (2005) Interstitial lung disease in mixed connective tissue disease. Orv Hetil 146(48):2435–2443PubMed

154.

Kawano-Dourado L, Baldi BG, Kay FU, Dias OM, Gripp TE, Gomes PS, Fuller R, Caleiro MT, Kairalla RA, Carvalho CR (2015) Pulmonary involvement in long-term mixed connective tissue disease: functional trends and image findings after 10 years. Clin Exp Rheumatol 33(2):234–240PubMed

155.

Narula N, Narula T, Mira-Avendano I, Wang B, Abril A (2018) Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement. Clin Exp Rheumatol 36(4):648–651PubMed

156.

Gunnarsson R, El-Hage F, Aalokken TM, Reiseter S, Lund MB, Garen T, Msg N, Molberg O (2016) Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 55(1):103–108. https://doi.org/10.1093/rheumatology/kev300CrossRef

157.

Fagundes MN, Caleiro MT, Navarro-Rodriguez T, Baldi BG, Kavakama J, Salge JM, Kairalla R, Carvalho CR (2009) Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med 103(6):854–860. https://doi.org/10.1016/j.rmed.2008.12.018CrossRefPubMed

158.

Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, Husain AN, Montner S, Chung JH, Cottin V, Fischer A, Noth I, Vij R, Strek ME (2016) Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 47(6):1767–1775. https://doi.org/10.1183/13993003.01565-2015CrossRefPubMedPubMedCentral

159.

Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A (2016) Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respir Med 119:150–154. https://doi.org/10.1016/j.rmed.2016.09.002CrossRefPubMed

160.

Ahmad K, Barba T, Gamondes D, Ginoux M, Khouatra C, Spagnolo P, Strek M, Thivolet-Bejui F, Traclet J, Cottin V (2017) Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 123:56–62. https://doi.org/10.1016/j.rmed.2016.10.017CrossRefPubMed

161.

Ito Y, Arita M, Kumagai S, Takei R, Noyama M, Tokioka F, Nishimura K, Koyama T, Notohara K, Ishida T (2017) Serological and morphological prognostic factors in patients with interstitial pneumonia with autoimmune features. BMC Pulm Med 17(1):111. https://doi.org/10.1186/s12890-017-0453-zCrossRefPubMedPubMedCentral

162.

Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Colaci M, Pavone M, Pignataro F, Del Papa N, Palmucci S, Vancheri C (2019) Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. Respir Med 150:154–160. https://doi.org/10.1016/j.rmed.2019.03.011CrossRefPubMed

163.

Sebastiani M, Cassone G, De Pasquale L, Cerri S, Della Casa G, Vacchi C, Luppi F, Salvarani C, Manfredi A (2020) Interstitial pneumonia with autoimmune features: a single center prospective follow-up study. Autoimmun Rev 19(2):102451. https://doi.org/10.1016/j.autrev.2019.102451CrossRefPubMed

164.

Sambataro G, Vancheri A, Torrisi SE, Colaci M, Pavone M, Libra A, Martorana E, Rosso R, Pignataro F, Del Papa N, Malatino L, Palmucci S, Sambataro D, Vancheri C (2020) The morphological domain does not affect the rate of progression to defined autoimmune diseases in patients with interstitial pneumonia with autoimmune features. Chest 157(1):238–242. https://doi.org/10.1016/j.chest.2019.08.2175CrossRefPubMed

165.

Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, Lundberg IE (2008) Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 59(5):677–685. https://doi.org/10.1002/art.23571CrossRefPubMed

166.

Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Byron J, Sahhar J, Roddy J, Gabbay E, Youssef P, Nash P, Zochling J, Proudman SM, Stevens W, Nikpour M (2013) Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 52(1):155–160. https://doi.org/10.1093/rheumatology/kes289CrossRef

167.

Christopher P, Denton CJFL, Goldin J, Kim G, Kuwana M, Allanore Y, Batalov A, Butrimiene I, Carreira P, Matucci-Cerinic M, Distler O, Kaliterna DM, Mihai C-M, Mogensen M, Olesińska M, Pope JE, Riemekasten G, Rodriguez-Reyne TS, Santos MJ, Van Laar J, Spotswood H, Siegel J, Jahreis A, Furst DE, Khanna D (2019) Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc). Eur Respir J. https://doi.org/10.1183/13993003CrossRef

168.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V (2020) Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 8(2):147–157. https://doi.org/10.1016/S2213-2600(19)30341-8CrossRefPubMed

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study

Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidosis Patients Infected with SARS‑CoV‑2

Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?

Quantitative Pectoralis Muscle Area is Associated with the Development of Lung Cancer in a Large Lung Cancer Screening Cohort

Change in Dynamic Hyperinflation After Bronchoscopic Lung Volume Reduction in Patients with Emphysema

Blood Cell Count Derived Inflammation Indexes in Patients with Idiopathic Pulmonary Fibrosis